Medical materials

Publication
  • EULAR •
  • 12 June, 2024 •
  • •

Long-term improvements in serum uric acid levels, gout symptoms, and safety up to 12-months with SEL-212 in gout refractory to conventional therapy: Results from the DISSOLVE I Phase 3, double-blind, placebo-controlled clinical trial

Alan Kivitz, Atul Singhal, Anand Patel, Kwabena Ayesu , Joanna Sobierska, Hugues Santin-Janin, Wesley DeHaan, Rehan Azeem, Peter Traber, Herbert Baraf

Available materials

Poster
Publication
  • EULAR •
  • 12 June, 2024 •
  • •

Once-monthly SEL-212 demonstrates efficacy and safety for up to 6-months in gout refractory to conventional therapy: Combined data from the DISSOLVE I & II Phase 3, double-blind, placebo-controlled clinical trials

Herbert Baraf, Puja Khanna, Anand Patel, Atul Singhal, Joanna Sobierska, Hugues Santin-Janin, Rehan Azeem, Wesley DeHaan, Peter Traber, Alan Kivitz

Available materials

Poster
Publication
  • EULAR •
  • 12 June, 2024 •
  • •

Health-related quality of life (HRQoL) and other secondary clinical outcomes in adults with gout refractory to conventional therapy treated with SEL-212: Pooled 6-month data from the phase 3 DISSOLVE I & II clinical trials

Puja Khanna, Anand Patel, Atul Singhal, Alan Kivitz, Joanna Sobierska, Hugues Santin-Janin, Nana Kragh, Rehan Azeem, Wesley DeHaan, Peter Traber, Herbert Baraf

Available materials

Poster
Sign up for alerts